Attenuation of GVHD for allo-bone marrow transplantation recipient by fasL-fas pathway in an H-2 haplotype disparate mouse combination

Abstract

In order to explore a new special and effective way to prevent, graft versus, host disease (GVHD) after allogenic bone marrow transplantation (alle-BMT), the stem cell antigen-1 (Sea-1) carly hematopoietic cells (EHC) from BALB/c mouse (H-2^d) were introduced with exogenous mouse Fas ligand (mFasL) cDNA gene by the retrevirus-mediated gene transfer and expanded for one week, and then they were co-cultured with the spleen mononuclear cells (SMNC) from BAC mouse (H-2^{d, h}) as one way mixed lymphocyte reaction (OWMLR). The cytotoxicity of treated BAC mouse SMNC against Na₂⁵¹CrO₄ labeling SMNC from BALB/c mouse was observed. The bone marrow mononuclear cells (BMMNC) from BAC mouse treated by the above methods were transplanted into lethally-irradiated congenic BALB/c mice to observe the occurrence of GVHD. The results showed that the SMNC from BAC mouse after OWMLR with exogenous mFasL cDNA gene-transduced hematopoietic cells (HC) from BALB/c mouse in a ratio of 1 to 5 exhibited an obvious inhibition of the cytotoxicity against the BALB/c mouse spleen cells at different effector/target ratios as compared to the control group (P<0.01). The grade I GVHD or no GVHD and the 80% survival rate at day 60 post-BMT were observed in the BALB/c mouse receiving BAC mouse BMMNC treated with similar way, while the grade II–III GVHD and the 20% survival rate were noted in the control group (P<0.01). It is suggested that the attenuation of GVHD in allo-BMT recipient could be successfully achieved through FasL-Fas pathway in an H-2 haplotype disparate mouse combination.

Keywords

Fas ligand / Fas / allogenic bone marrow transplantation / graft versus host disease

References

[1] SudaT, TakahashiT, GolsteinP, et al. . Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 1993, 751169-1169

[2] IauH T, YuM, FantanaA, et al. . Preventing of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science, 1996, 273109-109

[3] MorrisP T, CastroM G, LowensteinP R, et al. . Fas ligand-transfected myoblasts and islet cell transplantation. Transplantation, 2000, 69(9): 1972-1972

[4] LiuL B, ZouP, GuoR, et al. . Bioactivities of culture supernatants from retroviral packaging cells carrying the mouse Fas ligand gene. J Tongji Med Univ, 2001, 21(3): 215-215

[5] MinW P, GorczynskiR, HuangX Y, et al. . Dentritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsivene and prolong allograft survival. J Immunol, 2000, 164161-161

[6] BaD N. Application of Current Immunological Techniques (Chinese), 1998, Beijing, Publishing House of Beijing Medical University and China Union Medical University: 172-215

[7] Cavazzana-CalvoM, StephanJ L, SamackiS, et al. . Attenuation of graft-versus-host disease and graft rejection byEx Vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood, 1994, 83(1): 283-283

[8] IwasakiT, HamanoT, SahekiK, et al. . Graft-versushost-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway. Immunology, 2000, 99(1): 94-94

[9] HeC M, ShiB Y. Immunology of Organ Transplantation (Chinese, 1995, Beijing, Publishing House of People’s Military Medicine: 268-283

[10] TraycoffC M, CornettaK, YoderM C, et al. . Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential. Exp Hematol, 1996, 24299-299

[11] AustinT W, SalimiS, VeresG, et al. . Long-term multilineage expression in peripheral blood from a Moloney murine leukemia virus vector after serial transplantation of transduced bone marrow cells. Blood, 1999, 95829-829

[12] Cavazzana-CalvoM, FromontC, DeistF L, et al. . Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor β chain-specific immunotoxin. Transplantation, 1990, 501-1

[13] O’ConnellJ O, O’SullivanG C, CollinsJ K, et al. . The Fas counterattack: Fas mediated T cell killing by colon cancer cells expressing Fas ligang. J Exp Med, 1996, 1841075-1075

[14] LiJ Z, WangH L, HanZ C. Experimentology, of Blood (Chinese), 1997, Shanghai, Shanghai Publishing House of Science and Technology: 622-622